Background: In the pathogenesis of inflammatory bowel disease (IBD), the advanced glycation end product receptor (RAGE) has been involved. IBD is classified into Chron’, s disease (CD) and ulcerative colitis (UC). The promoter gene of the RAGE gene was discovered to have had unique polymorphisms that increased its transcriptional activity. This study, therefore, used a systematic review and meta-analysis to examine the relationship between the RAGE gene polymorphism and the risk of IBD. Methods: Databases such as PubMed, Scopus, and Cochrane library were searched to identify the relationship between RAGE gene polymorphisms and IBD susceptibility. We identified three Single Nucleotide Polymorphism (SNPs) (RAGE-429T/C, 374T/A, and G82S). The data were analyzed by RevMan 5. 4. Results: Four studies (932 cases/1366 controls) were included. The findings showed no relationship between RAGE –, 429T/C and –, G82S polymorphisms and the risk of IBD in all genetic models significantly. TT genotype of RAGE –, 374T/A polymorphisms was related to increased CD risk (OR=1. 37,95%CI=1. 04-1. 81,P=0. 02), while TA genotype was determined to be a protective factor (OR=0. 75,95%CI=0. 57-0. 99,P=0. 04). In UC, A allele of RAGE-374T/A was related to increase risk (OR=1. 26,95%CI=1. 04-1. 53,P=0. 02), while T allele was determined to decrease risk (OR=0. 79,95%CI= 0. 65-0. 96,P=0. 02). Conclusions: Our findings demonstrated that TT genotype and A allele of RAGE 374T/A polymorphisms were related to CD and UC risks, respectively, while the TA genotype and T allele possibly had a protective effect. RAGE –, 429T/C and RAGE –,G82S polymorphisms were not related to increased IBD risk.